A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma
Phase of Trial: Phase II
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs DCVAC OvCa (Primary) ; Carboplatin; Gemcitabine
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors SOTIO
- 19 Mar 2019 According to a SOTIO media release, David Cibula, MD, PhD from General University Hospital in Prague is the principal investigator of this study.
- 19 Mar 2019 Results were presented in a SOTIO media release.
- 19 Mar 2019 According to a SOTIO media release, results from this study were presented at 2019 SGOs 50th Annual Meeting on Womens Cancer.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History